Literature DB >> 29421969

Management and Outcome of Prosthetic Vascular Graft Infections: A Single Center Experience.

Maxime Elens1, Muzhakkir Dusoruth1, Parla Astarci1, Stefano Mastrobuoni1, Michel J Bosiers2, Jane Nardella1, Valérie Lacroix1, Julien Possoz1, Robert Verhelst1.   

Abstract

BACKGROUND: Prosthetic vascular graft infection (PVGI) remains a severe and challenging complication in vascular surgery with high morbidity and mortality rates. Incidence has been reported between 1% and 6%. The aim of this study was to report our experience in terms of general and surgical management as well as outcome, over 15 years.
METHODS: A retrospective consecutive study was conducted of all patients treated in our department for PVGI between January 2000 and December 2015. We analyzed all data relative to primary operation, duration interval between initial surgery and infections signs, infection site, type of microorganism involved, and surgical treatment modality, as well as evaluation of short- and long-term results.
RESULTS: Sixty-two patients were admitted for PVGI. Primary revascularization procedures consisted of a peripheral bypass in 42 (68%) patients and an aortic bypass in the remaining 20 (32%) patients. Median interval between primary procedure and reintervention was 3 months (interquartile range 17 [IQR 17]) in the peripheral group and 48 months (IQR 70.5) in the aortic group. Complete excision of the prosthetic graft was carried out in 85% of the cases. Thirty-day mortality was 0% and 9.5% in the aortic and peripheral group, respectively. The overall survival rate was 62.3% at 2-years, 46.4% in the aortic group, and 69.7% in the peripheral group.
CONCLUSIONS: Prosthetic vascular graft infection needs a multidisciplinary management with appropriate antibiotherapy, radical removal of the infected graft, and in situ reconstruction. This strategy gives satisfactory results in terms of mortality, morbidity, patency rates, and infection control.

Entities:  

Keywords:  infection; prosthetic; synthetic; vascular graft

Mesh:

Substances:

Year:  2018        PMID: 29421969     DOI: 10.1177/1538574418754453

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  1 in total

1.  Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface.

Authors:  Evgeny A Idelevich; Dennis Knaack; Nyityasmono Tri Nugroho; Georg Peters; Theodosios Bisdas; Sonja Molinaro; Giovanni B Torsello; Karsten Becker; Monika Herten
Journal:  Med Microbiol Immunol       Date:  2019-10-17       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.